Open Markets Calls on FTC to Block Pharma Mega-Merger That Would Create ‘Generic Drug Powerhouse’

Washington, D.C. — Today, the Open Markets Institute calls on the Federal Trade Commission to block the just-announced merger of Mylan and Pfizer’s Upjohn unit, which recently headquartered in China. The merger would create a “global generic drug powerhouse” and exacerbate skyrocketing drug prices.

Mylan and Pfizer are among several generic drugmakers under investigation by federal prosecutors and state attorneys general for allegedly colluding to inflate the prices of generic drugs by as much as a thousand percent. 

For more information:

America’s Concentration Crisis, Vol. II: Healthcare
Open Markets: High Drug Prices & Monopoly